| 1 |
35198978 | Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy. | 2022 |
1 |
| 2 |
35447344 | The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. | 2022 Jul 1 |
2 |
| 3 |
35587267 | Antibody-Mediated Screening of Peptide Inhibitors for Monoamine Oxidase-B (MAO-B) from an Autodisplayed FV Library. | 2022 Jun 15 |
1 |
| 4 |
35624406 | Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer. | 2022 Jun |
1 |
| 5 |
32476010 | Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites. | 2021 Feb 6 |
1 |
| 6 |
33759401 | Selegiline reduces daytime sleepiness in patients with Parkinson's disease. | 2021 May |
1 |
| 7 |
33818516 | Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. | 2021 Nov |
1 |
| 8 |
34290084 | Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease. | 2021 Sep 1 |
1 |
| 9 |
34352710 | Biphenylpiperazine Based MAO Inhibitors: Synthesis, Biological Evaluation, Reversibility and Molecular Modeling Studies. | 2021 Oct |
1 |
| 10 |
34553601 | Identification of a Chlorogenic Ester as a Monoamine Oxidase (MAO-B) Inhibitor by Integrating "Traditional and Machine Learning" Virtual Screening and In Vitro as well as In Vivo Validation: A Lead against Neurodegenerative Disorders? | 2021 Oct 6 |
1 |
| 11 |
34784871 | How to optimize the effectiveness and safety of Parkinson's disease therapy? - a systematic review of drugs interactions with food and dietary supplements. | 2021 Nov 16 |
1 |
| 12 |
34867348 | Monoamine Oxidase-B Inhibitor Reduction in Pro-Inflammatory Cytokines Mediated by Inhibition of cAMP-PKA/EPAC Signaling. | 2021 |
1 |
| 13 |
34970960 | The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update. | 2021 Dec 31 |
1 |
| 14 |
31146671 | Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7- Trimethylxanthine Hydrazones with In-vitro Neuroprotective and MAO-B Inhibitory Activities. | 2020 |
2 |
| 15 |
31562557 | Selegiline: a molecule with innovative potential. | 2020 May |
2 |
| 16 |
31589885 | The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. | 2020 Jan 1 |
1 |
| 17 |
32189109 | Retraction Note to: Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. | 2020 Apr |
1 |
| 18 |
32858935 | Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study. | 2020 Aug 26 |
1 |
| 19 |
33114548 | Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding. | 2020 Oct 26 |
1 |
| 20 |
30160213 | Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. | 2019 |
1 |
| 21 |
30857558 | Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. | 2019 Mar 11 |
1 |
| 22 |
30906861 | Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease. | 2019 Mar |
1 |
| 23 |
31264403 | Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline. | 2019 Aug 21 |
2 |
| 24 |
29221756 | Characterization of the binding site for d-deprenyl in human inflamed synovial membrane. | 2018 Feb 1 |
1 |
| 25 |
29279995 | Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons. | 2018 Nov |
2 |
| 26 |
29309800 | Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions. | 2018 Mar |
4 |
| 27 |
29417334 | Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. | 2018 Nov |
2 |
| 28 |
29498006 | Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease. | 2018 Oct |
2 |
| 29 |
29526790 | Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. | 2018 Jul 16 |
1 |
| 30 |
29532287 | Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. | 2018 Oct |
2 |
| 31 |
29671581 | Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of Their Therapeutic Activity, Pharmacokinetic and Toxicity Properties. | 2018 Jul 18 |
1 |
| 32 |
29847694 | A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. | 2018 Sep |
3 |
| 33 |
29955193 | Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. | 2018 May-Jun |
1 |
| 34 |
30016860 | Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases. | 2018 Aug 23 |
2 |
| 35 |
30077198 | Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease. | 2018 Aug |
1 |
| 36 |
30272370 | L‑Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration. | 2018 Dec |
2 |
| 37 |
30341696 | Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. | 2018 Nov |
1 |
| 38 |
28108387 | Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells. | 2017 Feb 15 |
4 |
| 39 |
28299453 | Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. | 2017 Jun |
1 |
| 40 |
28301816 | MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. | 2017 May 5 |
1 |
| 41 |
28359327 | Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. | 2017 Mar 31 |
1 |
| 42 |
28550482 | Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. | 2017 Jun |
2 |
| 43 |
28577058 | Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. | 2017 Sep |
5 |
| 44 |
28738644 | Biosensor for the characterisation of hMAO B inhibitors and the quantification of selegiline. | 2017 Nov 1 |
1 |
| 45 |
29114238 | Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance. | 2017 |
1 |
| 46 |
29229003 | Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. | 2017 Dec 11 |
1 |
| 47 |
25604428 | Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. | 2016 Feb |
1 |
| 48 |
26585057 | In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. | 2016 Feb |
2 |
| 49 |
26590367 | The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine. | 2016 Feb 1 |
1 |
| 50 |
26964672 | Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors. | 2016 Apr 15 |
1 |